Madopark

Levodopa/Benserazide, the active ingredients in Madopark, is an antiparkinson agent presented as a tablet for oral use. It treats Parkinson's disease and related Parkinsonian syndromes in adult patients by restoring dopamine levels in the brain.

GNH USA supplies Madopark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides full regulatory documentation to support import and distribution in multiple markets. Madopark is sourced from EU‑approved manufacturers ensuring consistent potency and compliance with European pharmacopeial specifications.

Madopark, an antiparkinson agent, is indicated for several Parkinsonian conditions.

Parkinson's disease: improves motor function and reduces rigidity and bradykinesia. Parkinsonian syndrome: alleviates tremor, stiffness, and gait disturbances. Secondary Parkinsonism: helps control symptoms when caused by medication or other neurological disorders.

Adverse reactions to Madopark vary in frequency and severity.

Common Side Effects: - Nausea - Orthostatic hypotension - Dizziness - Dry mouth

Serious or Rare Side Effects: - Dyskinesia - Hallucinations - Severe hypotension - Neuroleptic malignant‑like syndrome

When prescribing Madopark, clinicians should consider several precautionary measures to ensure safe use.

Dose titration: start with a low dose and increase gradually to minimize side effects. Renal impairment: adjust dose as needed. Hepatic dysfunction: use with caution. Concomitant MAO‑B inhibitors: avoid within 14 days. Pregnancy and lactation: safety not established; use only if benefit outweighs risk. Store at ambient temperature: keep in original container, protect from moisture and light.

Madopark can interact with other medicines; awareness of the interaction level helps guide monitoring.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis. - Anticholinergic drugs: may mask Parkinsonian symptoms. - High‑dose vitamin B6 (pyridoxine): reduces levodopa efficacy.

Moderate Interactions (Monitor Closely): - Selective MAO‑B inhibitors: may increase levodopa levels; monitor for dyskinesia. - Antihypertensive agents: additive hypotensive effect. - Iron supplements: decrease levodopa absorption; separate dosing by at least 2 hours.